Home Neuronal Signaling 5-HT Receptor agonist 1-Phenylbiguanide

research use only

1-Phenylbiguanide 5-HT Receptor agonist

Cat.No.S2578

1-Phenylbiguanide (Phenylbiguanide, PBG, N-Phenylbiguanide) is a 5-hydroxytryptamine3 (5-HT3) receptor agonist with EC50 of 3.0 μM.
1-Phenylbiguanide 5-HT Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 177.21

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S257801 DMSO]35 mg/mL]false]Water]35 mg/mL]false]Ethanol]17 mg/mL]false Purity: 99.50%
99.50

Chemical Information, Storage & Stability

Molecular Weight 177.21 Formula

C8H11N5

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 102-02-3 -- Storage of Stock Solutions

Synonyms Phenylbiguanide, PBG, N-Phenylbiguanide Smiles C1=CC=C(C=C1)N=C(N)N=C(N)N

Solubility

In vitro
Batch:

DMSO : 35 mg/mL (197.5 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 35 mg/mL

Ethanol : 17 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
5-HT3 receptor [1]
(Cell-free assay)
3.0 μM(EC50)
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06047574 Recruiting
Polycystic Ovary Syndrome
Shanghai 10th People''s Hospital
 September 18 2023 --
NCT05856578 Active not recruiting
Type 2 Diabetes Mellitus
Nanjing First Hospital Nanjing Medical University
 March 15 2022 Phase 4
NCT05892224 Recruiting
Obesity|Functional Neuroimaging
Shanghai 10th People''s Hospital
 January 1 2022 --
NCT04690634 Completed
Polycystic Ovary Syndrome
Shanghai 10th People''s Hospital
 May 1 2020 Not Applicable
NCT04700839 Completed
Polycystic Ovary Syndrome
Shanghai 10th People''s Hospital
 May 1 2020 Phase 4
NCT04373967 Unknown status
Type 2 Diabetes
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
 April 29 2020 Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map